To confirm these results, and to investigate whether anti-TGF-β enhances the anti-tumor efficacy of the FDA-approved anti-PD-L1 antibody atezolizumab, human PD-L1 knock-in mice bearing subcutaneous (s.c.)colon carcinoma MC38 tumors expressing Hu-PD-L1 (Hu-PD-L1-MC38) were treated with vehicle, anti-PD-L1, or a combination of anti-PD-L1 plus anti-TGF-β. Here, CD274 is linked to neoplasm.